Slide 1: Cover letter to BSE on investor presentation
ed port Sag a %< i eT & % eR inh * * a U LE S$ Pa ni a felaal olds € LIMITED nvironmenta Fe eT SEI ve can \ Management # Management Hei toh pale SME ee 1K, we MANAGEMENT SYSTEMS S with @ CORP & REGD OFFICE : “ TRIDENT TOWERS” No. 23, 4th Floor, 100 feet Road, Jayanagar 2nd Block, Bangalore-560011 Ph
Slide 2: Investor Presentation February 2022
naturalcapsules.com investor Presentation FEBRUARY, 2022
Slide 3: Safe Harbor
Safe Harbor PRESENTATION Certain statements and opinions with respect to the anticipated future performance of Natural Capsules Limited (NCL) in the presentation (“forward - looking statements”), which reflect various assumptions concerning the strategies, objectives and INVESTOR anticipated results
Slide 4: Inside this document
Inside this document PRESENTATION INVESTOR COMPANY BUSINESS SUSTAINABILITY OVERVIEW CANVAS a FINANCIAL INVESTMENT QUARTERLY wu —_ PERFORMANCE MERITS HIGHLIGHTS = oa n wu oa —) n a ¢ 1) oa ¢ a oo) —_ ¢ ra w
Slide 5: Company Overview
naturalcapsules.com Company Overview
Slide 6: Introducing Natural Capsules Limited (NCL)
Introducing Natural Capsules Limited (NCL) PRESENTATION Natural Capsules Limited (NCL) is a hard capsule shell manufacturer, who pioneered manufacturing of vegetarian capsules in India and is the second largest Indian manufacturer for gelatin capsules. The company was incorporated as a Public Limite
Slide 7: Our Journey
Our Journey PRESENTATION 1993- 2014: EARLY SUCCESSES AND A PERIOD OF EXPANSION INVESTOR 1993-95 2001 ¢ NCL was * Soon after, in 2001, ¢ 2003 was an ° The coming decade * In 2005-2007, NCL * In 2009-2012, © In 2012-14, NCL incorporated in NCL became the important witnessed a series acquired 5 lines N
Slide 8: Our Journey: 2015-2018 hurdles and going forward
2015 — 2018: THE HURDLES WE GOING FORWARD FACED ON THE WAY 2015 - 18 By Q2FY22, four new generation machines were commissioned, Fall in oil and commodity prices led to economic 2019 onward NCL witnessed an increase in demand slowdown in African countries and caused a decline in in both domestic and
Slide 9: Product Offerings
Product Offerings PRESENTATION Natural Capsules Limited manufactures a vast array INVESTOR capsules, including vegetarian capsules which they have pioneered in India. The company in now foraying into API manufacturing with complex CAPSULES APIs high-end patented technology developed in-house, under
Slide 10: Global Presence
Global Presence PRESENTATION Natural Capsules exports to 37 countries across 4 continents, bringing in sizable AFRICA MIDDLE AN X-l ar) EAST ASIA revenue from its export. ¢ Mozambique ° Iraq INVESTOR ¢ Ivory Coast Ce GON Vel * Ghana CS) Za] i C=1 AN} Cn |e)0) % OF TOTAL SALES Ce NeXt a-) ¢ United Ar
Slide 11: Serving Leading Brands
Serving Leading Brands PRESENTATION With over 3 decades of experience in the pharma sector, NCL has garnered excellent CUSTOMERS FOR MORE THAN relationship with customers across 37 countries. The company is now focused on 10 YEARS INVESTOR acquiring customers who deal with regulated markets. ‘WR t37
Slide 12: Leadership Team
Leadership Team PRESENTATION INVESTOR Mr. Laxminarayan Mundra Mr. Satyanarayana Mundra Mr. Sushil Kumar Mundra Mr. Sunil Mundra WHOLE TIME DIRECTOR WHOLE TIME DIRECTOR DIRECTOR MANAGING DIRECTOR (an) uw S = a Yn uw a >) Yn a ¢ O a ¢ Mr. Pramod Kasat Mr. C P Rangachar Mr. Anjan Kumar Roy Mrs. Jyothi
Slide 13: Business Canvas
naturalcapsules.com Business Canvas
Slide 14: Capsules Segment
Capsules Segment PRESENTATION With almost three decades of experience in the industry, Natural Capsules Limited is a leading manufacturer of hard capsules in India, its products are Qnd exported to regulated and unregulated markets across the globe, following largest INVESTOR stringent applicable ru
Slide 15: Enhancing Capacities
Enhancing Capacities PRESENTATION Natural Capsules Limited has undergone recent CAPEX, to support its existing manufacturing capacity and to enable the company to capture market share in regulated markets. INVESTOR CAPSULES MANUFACTURING CAPACITY The ability to deliver faster % 38 Crores planned cap
Slide 16: API Segment
API Segment : ha Natural Capsules Limited is now foraying into the API business segment through us its wholly owned subsidiary - Natural Biogenex Private Limited (NBPL) Greenfield Capex at s incorporated in 2020. The APIs that will be manufactured are, Prednisolone, ramkun spread across © acres wn B
Slide 17: API Segment: products and capacities approved under PLI
API Segment (nia) : ¢ [ ) THE FOLLOWING PRODUCTS AND CAPACITIES HAVE BEEN APPROVED UNDER THE PLI SCHEME vm INR 96 Crores - planned capital s expenditure for setting up the facility DEXAMETHASONE ' > 10 MT 19 MT ° NCL will be the only = Planned Capacity Imports to India in FY21 manufacturer SE ea ~ 3
Slide 18: PLI Scheme incentive for critical APIs
The scheme intends to boost domestic manufacturing of identified KSMs, Drug Intermediates and APIs by attracting large investments in the sector and thereby reduce India’s import dependence in critical APIs. With a view to attain self-reliance and reduce import A committee on drug security constitut
Slide 19: Focus on R&D
Focus on R&D PRESENTATION NCL strongly believes in investing in R&D, to stay ahead of its peers and to consistently innovate. The Company’s recent entry into the API business is a 2 DSIR testament to its firm belief in R&D. INVESTOR Recognised state of the art R&D facilities R&D SPENDS & KEY AREAS O
Slide 20: Sustainability
naturalcapsules.com Sustainability
Slide 21: Sustainability
Sustainability PRESENTATION Initiatives Zero discharge facilities INVESTOR Solar power generation SOA 1 8 SITES Solar concentrated heat generation funded by IREDA and 1st company to receive UNIDO grant for patented solar concentrated heat generation dishes in India _—_ NCL believes in Recycling of o
Slide 22: ts a e a
7 =. at id | um £ “ ' /—_—" ws i a ind an —- Ps £ 7 ae ts a e ae | a e /)) 1 ‘oe -_- y - ) s [é
Slide 23: Profit & Loss Statement Summary
Profit & Loss Statement Summary PRESENTATION PARTICULARS (3 IN CRORES) FY17 FY18 FY19 FY20 FY21 INVESTOR Revenue from Operations 53.64 54.76 59.78 61.55 79.51 Other Income 0.81 0.81 1.13 0.95 0.73 Total Income 54.45 55.57 60.91 62.50 80.24 Total Operating Expenses 48.66 49.35 54.89 56.25 68.56 EBITD
Slide 24: Balance Sheet Summary
Balance Sheet Summary PRESENTATION PARTICULARS (3 IN CRORES) FY17 FY18 FY19 FY20 FY21 INVESTOR Total Equity (Networth) 53.96 54.32 55.49 55.62 62.12 Non Current Liabilities 2.27 2.17 1.23 1.08 1.08 Current Liabilities 15.10 14.56 17.61 17.98 33.45 Total Equity and Liability 71.33 71.05 74.33 74.68 9
Slide 25: Cash Flow Statement Summary
Cash Flow Statement Summary PRESENTATION PARTICULARS (3 In cRoRES) FY17 FY18 FY19 FY20 INVESTOR Cash Flow from Operating Activities 1.91 5.34 2.09 6.90 5.54 Cash Flow from Investing Activities (0.19) (0.93) (7.06) (5.74) (8.53) Cash Flow from Financing Activities (1.67) (3.92) 4.28 (1.18) 2.75 Net i
Slide 26: Investment Merits
naturalcapsules.com Investment Merits
Slide 27: Growth Drivers
Growth Drivers PRESENTATION Uy a ig uf INVESTOR Capacity enhancement with Being the only backward Exploring opportunities The Company will benefit from state-of-the-art machinery integrated manufacturer to set up capsules strong industry tailwinds on the in capsules division, enabling of steroidal A
Slide 28: Strategic Priorities
Strategic Priorities PRESENTATION NCL is geared to bring about monumental changes in its & iP INVESTOR approach towards its business. With the ongoing CAPEX, the STRATEGIC PRIORITY ACTIONS TAKEN Company is enabling itself to * Positioning the business to reduce margin * Collaborating with buyers who
Slide 29: Quarterly Highlights
naturalcapsules.com Quarterly Highlights
Slide 30: Quarterly Updates
Quarterly Updates REVENUES EBITDA ® 24.54% ® 44.17% ® 72.92% ® 128.27% EBITDA MARGINS PAT ®) 277 BPS ® 57.09% ®) 494 BPS ® 153.09% EPS KEY ® 55.50% ~ eee ® 150.97%
Slide 31: Management Commentary
Management Commentary PRESENTATION “I'm pleased to report that Natural Capsules Limited had a INVESTOR particularly strong quarter in Q3FY22. Ona quarterly basis, our net revenues increased by 24.54 %. The increase in the top line is due to a 9% increase in average realisation on a quarter- over-qua
Slide 32: CAPEX Tracker
CAPEX Tracker PRESENTATION Natural Capsules is geared to make significant capital expenditures in the quarters to come and is on track with its capsule business. The Company will focus on ramping up its endeavours in its API business in the coming quarters. INVESTOR Q3FY22 or ey okt Px) Q2FY23 Q3FY2
Slide 33: Profit & Loss Statement Summary (consolidated)
Profit & Loss Statement Summary (consolidated) PRESENTATION PARTICULARS (2 In CRORES) Q3FY21 Q2FY22 Q3FY22 Belsaess 9M FY22 REVENUE INVESTOR Revenue from Operations 21.75 30.20 37.61 56.4 93.52 Higher realisations and incremental volumes as a Other Income 0.02 0.10 0.06 0.53 0.2 result of additional
Slide 34: Thank You
( \( NATURAL naturalcapsules.com CAPSULES 85 umitep Thank You CONTACT US FOR FURTHER INFORMATION, PLEASE CONTACT Natural Capsules Limited Mrs. Shilpa Burman WV TemeAV eal edatsh a (clare) TRIDENT TOWERS, COMPANY SECRETARY INVESTOR RELATIONS ADVISOR Fourth Floor, No. 23, +91 95588 14500 100 Feet Road